<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">02872</article-id><article-id pub-id-type="doi">10.7554/eLife.02872</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Cyclin D activates the Rb tumor suppressor by mono-phosphorylation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-12773"><name><surname>Narasimha</surname><given-names>Anil M</given-names></name><aff><addr-line><named-content content-type="department">Department of Cellular and Molecular Medicine</named-content></addr-line>, <institution>University of California, San Diego School of Medicine</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12774"><name><surname>Kaulich</surname><given-names>Manuel</given-names></name><aff><addr-line><named-content content-type="department">Department of Cellular and Molecular Medicine</named-content></addr-line>, <institution>University of California, San Diego School of Medicine</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12775"><name><surname>Shapiro</surname><given-names>Gary S</given-names></name><aff><institution>Sanofi Oncology</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12776"><name><surname>Choi</surname><given-names>Yoon J</given-names></name><aff><addr-line><named-content content-type="department">Department of Genetics</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4845"><name><surname>Sicinski</surname><given-names>Piotr</given-names></name><aff><addr-line><named-content content-type="department">Department of Genetics</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-12441"><name><surname>Dowdy</surname><given-names>Steven F</given-names></name><aff><addr-line><named-content content-type="department">Department of Cellular and Molecular Medicine</named-content></addr-line>, <institution>University of California, San Diego School of Medicine</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country><email>sdowdy@ucsd.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1072"><name><surname>Davis</surname><given-names>Roger</given-names></name><role>Reviewing editor</role><aff><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>05</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02872</elocation-id><supplementary-material><ext-link xlink:href="elife-02872-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>23</day><month>03</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>05</month><year>2014</year></date></history><permissions><copyright-statement>Copyright Â© 2014, Narasimha et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Narasimha et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The widely accepted model of G1 cell cycle progression proposes that cyclin D:Cdk4/6 inactivates the Rb tumor suppressor during early G1 phase by progressive multi-phosphorylation, termed hypo-phosphorylation, to release E2F transcription factors.  However, this model remains unproven biochemically and the biologically active form(s) of Rb remains unknown.  Here we find that Rb is exclusively mono-phosphorylated in early G1 phase by cyclin D:Cdk4/6.  Mono-phosphorylated Rb is composed of 14 independent isoforms that are all targeted by the E1a oncoprotein, but show preferential E2F binding patterns.  At the late G1 Restriction Point, cyclin E:Cdk2 inactivates Rb by quantum hyper-phosphorylation.  Cells undergoing a DNA damage response activate cyclin D:Cdk4/6 to generate mono-phosphorylated Rb that regulates global transcription, whereas cells undergoing differentiation utilize un-phosphorylated Rb.  These observations fundamentally change our understanding of G1 cell cycle progression and show that mono-phosphorylated Rb, generated by cyclin D:Cdk4/6, is the only Rb isoform in early G1 phase.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>